Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Enterprise Value: 2021-2022

Historic Enterprise Value for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $75.1 million.

  • Cardiol Therapeutics' Enterprise Value fell 54.92% to $75.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$56.1 million, marking a year-over-year decrease of 131.47%. This contributed to the annual value of $14.5 million for FY2021, which is N/A change from last year.
  • Cardiol Therapeutics' Enterprise Value amounted to $75.1 million in Q3 2022, which was down 18.33% from $92.0 million recorded in Q2 2022.
  • Cardiol Therapeutics' 5-year Enterprise Value high stood at $166.6 million for Q3 2021, and its period low was -$15.2 million during Q2 2021.
  • Over the past 2 years, Cardiol Therapeutics' median Enterprise Value value was $19.9 million (recorded in 2022), while the average stood at $50.0 million.
  • Examining YoY changes over the last 5 years, Cardiol Therapeutics' Enterprise Value showed a top increase of 732.99% in 2022 and a maximum decrease of 54.92% in 2022.
  • Quarterly analysis of 2 years shows Cardiol Therapeutics' Enterprise Value stood at $14.9 million in 2021, then plummeted by 54.92% to $75.1 million in 2022.
  • Its last three reported values are $75.1 million in Q3 2022, $92.0 million for Q2 2022, and $19.9 million during Q1 2022.